particip piper jaffray healthcar pjhc consum survey provid read-
anim health coverag specif us companion anim consum
trend overal believ survey result support low-teen growth
expect model us companion anim modestli
lower y/i year survey provid posit indic slightli less posit
survey last year specif around modestli lower spend intent
favor trend increas pet per household remain tailwind still believ
under-penetrated dermatolog market provid strong growth opportun outsid
companion believ livestock fundament remain favor
grant less posit last year us cattle/beef fundament
expect remain strong import speci lift
estim incorpor manag preliminari tax guid pt
winter survey support growth expect posit survey
continu show trend increas pet per household key driver behind zoeti
companion anim growth increas survey suggest almost
respond plan increas number pet household compar
expect decreas spend expect
flat-to-down compar flat-to-up survey still model
low-teen growth us companion anim modestli less pronounc
believ survey result support posit indic
survey posit last year survey still suggest dermatolog
product under-penetrated usag low-to-mid teen rang although
seem lower awar may impact adopt zoeti product still
largest market posit although seem like usag apoquel may
impact altern product like benadryl
lift estim tax benefit price target increas manag provid
preliminari expect impact recent pass tax act expect
reduct net incom driven one-tim repatri
tax charg manag also expect full-year adjust effect tax rate
rang result lower tax rate ep estim move
ep estim increas although continu model
less pronounc top bottom line growth ep growth get back
low-teen percentag believ on-going resili growth profil support
elev multipl roll valuat multipl ep estim
use multipl price target increas previous base
ep lower multipl due longer time horizon
acquisit integr competit fx macro econom factor
zoeti lead global manufactur anim health medic vaccin
price close januari
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
survey support
expect us
particip winter piper jaffray healthcar pjhc consum survey around
consum dig companion anim health trend us respond nearli
pet compar nearli two-third last survey major
dog and/or cat posit survey continu show trend increas pet per household
key driver behind zoeti companion anim growth respond increas
number pet household compar decreas survey
suggest almost respond plan increas number pet household
compar expect decreas
ask spend healthcar per pet respond suggest mid-single-digit lower
spend compar although sourc lower spend seem driven
individu spent rel high-level pet healthcar
like result one-tim procedur spend expect
flat-to-down believ repres spend anim health product
impact zoeti previou survey spend expect flat-to-up
compar model us companion anim revenu growth
low-teen still wait result still model low-teen growth us
companion anim modestli lower growth believ survey
result support posit indic survey posit last year
expect similar low-teen growth intern companion anim support
trend increas adopt medic rate core growth market like china
overal us consum remain reluct purchas pet insur two-third question
respond state insur need third either consid intend
buy pet well plan year rel split consid intend littl
wait consid result consist previou survey ask
drive forc behind anim health purchas decis respond
state price biggest drive factor follow state vet recommend
nearli call product avail slightli higher compar last survey
last survey nearli respond call ease-of-us drive factor fell
survey consist last survey respond
consid referr advertis tv radio billboard respect decis driver
continu low impact advertis seen survey may headwind zoeti focus
new product direct-to-consum market grant campaign strong focu
new dermatolog portfolio continu under-penetrated
look zoeti core new growth product survey suggest anim
dermatolog still under-penetrated market survey less respond
state use dermatolog product compar last survey remain question
respond state use dermatolog product regard awar survey
mix last respond state notic increas sign
allergi cat and/or dog past year previous state
saw decreas allergi sign previou survey state chang
also consist last survey remain respons uncertain although sign
allergi less pronounc survey zoeti product apoquel cytopoint continu
show strong market share posit nearli respond use plan use
product altern product benadryl show modestli higher usage/plan
usag compar last survey larg expens apoquel
page
survey support
expect us
particip winter piper jaffray healthcar pjhc consum survey around
consum dig companion anim health trend us respond nearli
pet compar nearli two-third last survey major
dog and/or cat posit survey continu show trend increas pet per household
key driver behind zoeti companion anim growth respond increas
number pet household compar decreas survey
suggest almost respond plan increas number pet household
compar expect decreas
ask spend healthcar per pet respond suggest mid-single-digit lower
spend compar although sourc lower spend seem driven
individu spent rel high-level pet healthcar
like result one-tim procedur spend expect
flat-to-down believ repres spend anim health product
impact zoeti previou survey spend expect flat-to-up
compar model us companion anim revenu growth
low-teen still wait result still model low-teen growth us
companion anim modestli lower growth believ survey
result support posit indic survey posit last year
expect similar low-teen growth intern companion anim support
trend increas adopt medic rate core growth market like china
overal us consum remain reluct purchas pet insur two-third question
respond state insur need third either consid intend
buy pet well plan year rel split consid intend littl
wait consid result consist previou survey ask
drive forc behind anim health purchas decis respond
state price biggest drive factor follow state vet recommend
nearli call product avail slightli higher compar last survey
last survey nearli respond call ease-of-us drive factor fell
survey consist last survey respond
consid referr advertis tv radio billboard respect decis driver
continu low impact advertis seen survey may headwind zoeti focus
new product direct-to-consum market grant campaign strong focu
new dermatolog portfolio continu under-penetrated
look zoeti core new growth product survey suggest anim
dermatolog still under-penetrated market survey less respond
state use dermatolog product compar last survey remain question
respond state use dermatolog product regard awar survey
mix last respond state notic increas sign
allergi cat and/or dog past year previous state
saw decreas allergi sign previou survey state chang
also consist last survey remain respons uncertain although sign
allergi less pronounc survey zoeti product apoquel cytopoint continu
show strong market share posit nearli respond use plan use
product altern product benadryl show modestli higher usage/plan
usag compar last survey larg expens apoquel
page
million except per share data
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
sale
amort intang
net incom loss attribut non-controlling interest
net incom attribut zoeti
adjust report ep
depreci amort
net incom attribut zoeti
page
million except per share
total revenu speci
fish sheep
dog
revenu composit speci
fish sheep
dog
fish sheep
dog
page
million except per share
cash equival
receiv pfizer
properti plant equip
current portion alloc long-term debt
payabl pfizer
accru compens relat item
equiti attribut non-controlling interest
page
statement flow
million except per share
depreci amort
asset-write-off impair
net gain sale asset
chang asset liabil
total chang asset liabil
purchas properti plant equip
net proce sale asset
acquisit net cash acquir
increas short-term borrow net
purchas treasuri stock
issuanc long-term debt
payment pfizer
payment long-term debt
purchas subsidiari share
net financ activ pfizer
effect exchang rate chang
net increas cash cash equival
page
